Document is current

Article History

Accepted: 4 September 2023

First Online: 25 September 2023

Declarations

:

: The authors of this manuscript have been supported in part by Grants AI149431, DK078244, and DK082753 from the National Institutes of Health, and a gift from the IGA Nephropathy Foundation.

: JN is a co-founder and co-owner of and consultant for Reliant Glycosciences, LLC. JN is a co-inventor on US patent application 14/318,082 (assigned to UAB Research Foundation). JN has a sponsored research agreement with Travere Therapeutics. BAJ is a co-founder and co-owner of Reliant Glycosciences, LLC and a co-inventor on US patent application 14/318,082 (assigned to UAB Research Foundation). MBR is a co-founder and co-owner of and consultant for Reliant Glycosciences, LLC. MBR is a co-inventor on US patent application 14/318,082 (assigned to UAB Research Foundation). DVR received research funding from Reata Pharmaceuticals, Travere Therapeutics (Retrophin), Pfizer Pharmaceuticals, Calliditas Therapeutics (Pharmalink), Otsuka Pharmaceuticals (Visterra), Vertex Pharmaceuticals, Chinook Pharmaceuticals, consultancy fees from Novartis, GSK, George Clinical, Eledon Pharmaceuticals, Otsuka Pharmaceuticals (Visterra), Calliditas Therapeutics (Pharmalink), Chinook Pharmaceuticals. DVR is co-founder and co-owner of Reliant Glycosciences, LLC. None of the listed commercial entities contributed to this study. AR and TJG have nothing to disclose.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: DVR was responsible for conceptualization; DVR, BAJ were responsible for supervision; AR, TJG, MBR, JN and DVR wrote the different sections of the initial draft of the manuscript; all authors edited the manuscript. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work before and after publication.